The summary for the Image-guided Drug Delivery in Cancer (R01) Federal Grant is detailed below.
It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section.
If these sections are incomplete, please visit the website of the government agency that is offering this grant.
State governments - County governments - City or township governments - Special district governments - Public and State controlled institutions of higher education - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility
Other Eligible Applicants include the following: Eligible Agencies of the Federal Government; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; U.S. Territory or Possession.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), encourages innovative translational research in the development of quantitative in vivo imaging characterization of image-guided drug delivery (IGDD) in cancer, including characterizations of the target, delivery validation, and therapy response. This FOA will support research in development of integrated imaging-based platforms for multifunctional and multiplexed drug delivery systems in cancer. Validation studies in non-human primates or large animal models and first in human studies directed towards translation of IGDD technology into the clinic will be considered appropriate for this FOA. Mechanism of Support. This FOA will utilize the Research Project Grant (R01) grant mechanism. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.